Peer-to-Peer Connection with
Dr. Shawn Ryan,
Information to help reverse accidental opioid overdoses
Dr. Shawn Ryan,
MD, MBA, ABEM, ABAM
Listen in as Dr. Ryan discusses his clinic’s approach to addiction, the current opioid epidemic, and why access to NARCAN® is so vital.
FIRST and ONLY FDA-Approved Nasal Naloxone for Emergency Treatment of Opioid Overdose
- Concentrated 4mg dose
- Needle-free and designed for ease of use*
- Broad access and affordability†
NARCAN® Nasal Spray is not a substitute for emergency medical care.
Please see Indications and Important Safety Information
* Administer in accordance with the Instructions for Use. Repeated doses may be necessary.
† Based on data from IMS Health and MMIT Formulary Analytics
SEE HOW TO USE
NARCAN® NASAL SPRAY
In this video, you'll learn:
- How to recognize symptoms of an opioid overdose
- How to administer NARCAN® Nasal Spray
- How to proceed if the person regains consciousness before help arrives
Find answers to the most frequently asked questions about NARCAN® Nasal Spray.
What pharmacokinetic data is there to support the use of NARCAN® Nasal Spray?
In a pharmacokinetic study in 30 healthy adult subjects, the relative bioavailability (BA) of one nasal spray in one nostril (4 mg total dose, 0.1 mL of 40 mg/mL naloxone hydrochloride solution) and two nasal sprays administered as one nasal spray in each nostril (8 mg total dose, 0.1 mL of 40 mg/mL naloxone hydrochloride solution in each nostril) was compared to a single dose of 0.4 mg naloxone hydrochloride intramuscular injection.
The pharmacokinetic parameters obtained in the study are as follows:
Parameter 4mg – One Nasal Spray in one nostril 8 mg – Two Nasal Sprays, one in each nostril 0.4 mg Intramuscular Injection (N=29) (N=29) (N=29) tmax (h)* 0.50 (0.17, 1.00) 0.33 (0.17, 1.00) 0.38 (0.08, 2.05) Cmax (ng/mL) 4.83 (43.1) 9.70 (36.0) 0.88 (30.5) AUCt (hr.ng/mL) 7.87 (37.4) 15.3 (23.0) 1.72 (22.9) AUC0-inf(h*ng/mL) 7.95 (37.3) 15.5 (22.7) 1.76 (22.6) t1/2 (h) 2.08 (29.5) 2.10 (32.4) 1.24 (25.9)
*tmax reported as median (minimum, maximum)
Why the 4 mg dose?
The 4 mg dose in NARCAN® Nasal Spray was selected based on results from studies conducted in collaboration with the National Institute on Drug Abuse (NIDA). In clinical trials conducted to support the approval of NARCAN® Nasal Spray, administration of the drug in one nostril delivered approximately the same levels or higher of naloxone as a single dose of an FDA-approved naloxone intramuscular injection, and achieved these levels in approximately the same time frame.
How can I order NARCAN® Nasal Spray?
First responder organizations (EMS, law enforcement and fire departments) and community based naloxone distribution programs will be able to get NARCAN® Nasal Spray from authorized wholesalers, distributors and pharmacies.
Order forms can be downloaded here.
Additionally, ADAPT Pharma, the maker of this medication, has a dedicated customer service team to help group purchasers source NARCAN® Nasal Spray and place an order.
Can NARCAN® Nasal Spray be used on a child?
The safety and effectiveness of NARCAN® Nasal Spray has been established in pediatric patients for known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. Use of naloxone hydrochloride in pediatric patients is supported by evidence from adequate and well-controlled studies of naloxone hydrochloride in adults with additional data from 15 clinical studies (controlled and uncontrolled) in which neonates and pediatric patients received parenteral naloxone hydrochloride in doses ranging from 0.005 mg/kg to 0.01 mg/kg. Safety and effectiveness are also supported by use of other naloxone hydrochloride products in the postmarketing setting, as well as data available in the medical literature and clinical practice guidelines. NARCAN® Nasal Spray may be administered to pediatric patients of all ages.
Absorption of naloxone hydrochloride following intranasal administration in pediatric patients may be erratic or delayed. Even when the opiate-intoxicated pediatric patient responds appropriately to naloxone hydrochloride, he/she must be carefully monitored for at least 24 hours, as a relapse may occur as naloxone hydrochloride is metabolized. In opioid-dependent pediatric patients (including neonates), administration of naloxone hydrochloride may result in an abrupt and complete reversal of opioid effects, precipitating an acute opioid withdrawal syndrome. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal syndrome in adults, may be life threatening, if not recognized, and should be treated according to protocols developed by neonatology experts.
In settings such as in neonates with known or suspected exposure to maternal opioid use, where it may be preferable to avoid the abrupt precipitation of opioid withdrawal symptoms, consider use of an alternate naloxone containing product that can be dosed according to weight and titrated to effect.
Also, in situations where the primary concern is for infants at risk for opioid overdose, consider whether the availability of alternate naloxone-containing products may be better suited than NARCAN® Nasal Spray.
What are the side effects associated with the use of NARCAN® Nasal Spray?
The following adverse reactions were observed in a clinical study of NARCAN® Nasal Spray:
- Increased blood pressure
- Muscle spasms
- Musculoskeletal pain
- Nasal dryness
- Nasal edema
- Nasal congestion
- Nasal inflammation
Adverse reactions have been identified during post-approval use of naloxone hydrochloride in the postoperative setting:
- Ventricular tachycardia and fibrillation
- Pulmonary edema
- Cardiac arrest
Death, coma and encephalopathy have been reported as sequelae of these events. Excessive doses of naloxone hydrochloride in postoperative patients have resulted in significant reversal of analgesia and have caused agitation.
Abrupt reversal of opioid effects in persons who were physically dependent on opioids has precipitated signs and symptoms of opioid withdrawal including:
- Body aches
- Runny nose
- Shivering or trembling
- Nervousness, restlessness or irritability
- Nausea or vomiting
- Abdominal cramps
- Increased blood pressure
In some patients, there may be aggressive behavior upon abrupt reversal of an opioid
In the neonate, opioid withdrawal signs and symptoms also included:
- Excessive crying
- Hyperactive reflexes
Are there any contraindications?
Patients should not use NARCAN® Nasal Spray if they are allergic to naloxone hydrochloride or any other ingredients:
- Benzalkonium chloride (preservative)
- Disodium ethylenediaminetetraacetate (stabilizer)
- Sodium chloride
- Hydrochloric acid (to adjust pH)
- Purified water
Are there any other safety considerations concerning the use of NARCAN® Nasal Spray?
Click here to view the Important Safety Information
NARCAN® NASAL SPRAY AFFORDABILITY
Affordability and access to NARCAN® Nasal Spray are important priorities for ADAPT Pharma, and we have partnered with all major wholesalers, distributors, and retail pharmacies to ensure broad-based availability. For NARCAN® Nasal Spray, ADAPT Pharma has collaborated with major Pharmacy Benefits Managers and insurance companies (including Medicaid), to help make sure the cost of NARCAN® Nasal Spray to insured patients and caregivers is reasonable and affordable.
For your patients, their caregivers and individual purchasers:
Many insured patients, caregivers, and individuals can purchase NARCAN® Nasal Spray for $10 or less. In fact, 94% of insured lives in the US have coverage for NARCAN® Nasal Spray*. And according to IMS Health, nearly three quarters (74%) of prescriptions for NARCAN® Nasal Spray have a co-pay of $10 or less**. For those who choose to pay by cash, ADAPT Pharma has partnered with retail pharmacies to make NARCAN as affordable as possible.
Please contact your health insurance provider to find out your coverage and co-pay requirements for NARCAN® Nasal Spray.
Find a NARCAN participating pharmacy near you
ADAPT Pharma has partnered with all major wholesalers, distributors, and retail pharmacies to make NARCAN® as accessible and affordable as possible. And at many locations, your patients DO NOT NEED A PRESCRIPTION to obtain NARCAN Nasal Spray. Enter your zip code for a listing of NARCAN® participating pharmacies — then call ahead for information on pricing, copays, and whether you will need a prescription.
* MMIT Formulary Analytics November 2016
** IMS Health, NPA Extended Insights Audit, March 2017.
FOR QUALIFYING GROUP PURCHASERS:
To expand community access, NARCAN® Nasal Spray is available to all qualified group purchasers for $37.50 per 4mg dose ($75 per carton of 2 doses). This pricing is available for all Qualified Group Purchasers, such as first responders (EMS, Fire Department, Police), community organizations and Departments of Health, regardless of size. This pricing represents a 40% discount off the Wholesale Acquisition Cost (WAC) of $125 per carton.
If you would like to make a group qualified purchase, click here.